Pharmaceuticals Sector - Solvay

80
Solvay Global Annual Report 2005
Finance lease obligations
EUR million Minimum lease payments Present value of minimum
lease payments
Amounts payable under fi nance leases : 2004 2005 2004 2005
Within one year 4 5 4 4
In years two to fi ve inclusive 12 12 11 10
Beyond fi ve years 10 6 9 5
Less: future fi nance charges -2 -4
Present value of Lease Obligations 24 19 24 19
Less : Amount due for settlement within 12 months 4 4
Amount due for settlement after 12 months 20 15
Operating lease obligations
EUR million 2004 2005
Total minimum lease payments under operating leases recognized in the income statement
of the year
38 43
EUR million 2004 2005
Within one year 36 46
In years two to fi ve inclusive 107 138
Beyond fi ve years 78 68
Total of future minimum lease payments under non-cancellable operating leases 221 252
(26) Other investments
EUR million 2004 2005
Fair value at 1 January 531 590
Disposed of during the year -34 -16
Acquired during the year 51 31
Increase (decrease) in fair value 37 105
Other 5 -4
Fair value at 31 December 590 706
Of which recognized directly in equity 80 185
This heading contains the fi nancial assets held for sale. It contains the shares held in Fortis, Sofi na, Innogenetics
and Arqule as well as companies of non-signifi cant size which are neither consolidated nor accounted for by the
equity method. Fortis and Sofi na are not allocated to segments, whilst Innogenetics and Arqule are allocated to
the Pharmaceuticals Sector. In 2004 this item also included Thai Olefi ns Company (TOC), allocated to the Plastics
Sector. This investment was sold in 2005.
At the end of 2004, in the absence of detailed information, Italmex was accounted for under “other investments”.
Since January 1, 2005 it has been included in the Solvay consolidated accounts.